PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Bratislavské lekárske listy/Bratislava medical journal0 citationsOpen Access

CHA2DS2-VASc Score for Predicting Recurrent Acute Coronary Syndrome and Heart Failure Following Acute Coronary Syndrome

ESEirin SakaguchiFujita Health University HospitalHNHiroyuki NaruseFujita Health University HospitalYIYuya IshiharaFujita Health University Hospital

Key Result

The CHA2DS2-VASc score independently predicted the composite of non-fatal recurrent acute coronary syndrome and heart failure hospitalization (HR 1.26 per 1-point increment) in patients with ACS.

Key Points

  • This research aims to evaluate the CHA2DS2-VASc score's effectiveness in forecasting recurrent acute coronary syndrome (ACS) and heart failure (HF) in ACS patients.
  • Enrolled 2,213 patients hospitalized for ACS who survived for 1 year after discharge.
  • Analyzed outcomes using multivariate Cox regression, independent of atrial fibrillation status.
  • Determined optimal CHA2DS2-VASc score cutoff at 4 points for predicting non-fatal events.
  • The primary outcome of recurrent ACS and HF hospitalization occurred in 81 patients (3.7%).
  • The CHA2DS2-VASc score was an independent predictor of recurrent ACS and HF admissions.
  • Combining the CHA2DS2-VASc score with NT-proBNP improved predictive accuracy for HF admission.

Study Design

Type

Cohort (n=2,213)

Multicenter

No

Structured PICO

Does the CHA2DS2-VASc score predict recurrent ACS and heart failure hospitalization in patients following an acute coronary syndrome?

P
Population
2,213 Japanese patients hospitalized for acute coronary syndrome (ACS) who survived for 1 year after discharge, mean age 68.5 years, 72% male. Included patients with STEMI (37%), NSTEMI (43%), and unstable angina pectoris (20%).
I
Intervention
CHA2DS2-VASc score assessment (evaluated as a continuous variable and with a cutoff of ≥4 points)
O
Outcome
Composite of non-fatal recurrent ACS and heart failure (HF) hospitalization during 12-month follow-upcomposite

The CHA2DS2-VASc score is a useful clinical tool for predicting the risk of non-fatal recurrent ACS and heart failure hospitalization in patients who have survived an initial ACS event, independent of atrial fibrillation status.

Main Result

Effect estimate: HR 1.26 (95% CI 1.11-1.44)

p-value: p=0.001

Limitations

  • Retrospective study design
  • Single-center study
  • Non-randomized nature of treatments
  • Relatively small number of outcome events
  • Enrolled only Japanese patients
  • Retrospective design
  • Single center
  • Non-randomized treatments
  • Relatively small number of outcome events (N=81)

Abstract

Abstract Recurrent acute coronary syndrome (ACS) and heart failure (HF) are the leading causes of readmission and are associated with a significantly worse prognosis than the original episode. This study aimed to assess the utility of the CHA 2 DS 2 -VASc score in predicting these events in patients with ACS. We enrolled 2,213 patients (1,603 men; mean age, 69 years) hospitalized for ACS who survived for 1 year after discharge. The primary outcome was the composite of non-fatal recurrent ACS and HF hospitalization. During the 12-month follow-up, the primary outcome was observed in 81 patients (3.7%), comprising 44 patients with recurrent ACS events and 37 with HF admissions. Multivariate Cox regression analyses revealed that the CHA 2 DS 2 -VASc score was an independent predictor of the primary outcome and HF admission, regardless of atrial fibrillation (AF) status, and included patients treated with primary percutaneous coronary intervention (PCI). The optimal CHA₂DS₂-VASc score cutoff value for predicting non-fatal events was 4 points. Integration of the CHA 2 DS 2 -VASc score with the N-terminal pro-B-type natriuretic peptide level improved the predictive accuracy for HF admission, as evidenced by higher C-index and net reclassification improvement values (both p < 0.05). In conclusion, the CHA 2 DS 2 -VASc score clearly identified high-risk patients based on recurrent ACS or admission for HF among those with ACS, irrespective of the presence of AF, and those undergoing primary PCI.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sakaguchi et al. (2026) conducted a cohort in Acute Coronary Syndrome (n=2,213). CHA2DS2-VASc score was evaluated on Composite of non-fatal recurrent acute coronary syndrome and heart failure hospitalization (HR 1.26, 95% CI 1.11-1.44, p=0.001). The CHA2DS2-VASc score independently predicted the composite of non-fatal recurrent acute coronary syndrome and heart failure hospitalization (HR 1.26 per 1-point increment) in patients with ACS.

synapsesocial.com/papers/69e47440010ef96374d90060https://doi.org/10.1007/s44411-026-00609-y
Ask AI
Helpful
Bookmark
Share
View Full Paper